All News

hand stopping falling dominos

Can we prevent psoriatic arthritis?

Antoni Chan, MD, PhD

Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few presentations on this topic that will help us understand this progression from PsO to PsA better.

Read Article
RA,polyarticular,black,rheumatoid

EULAR 2024: New drugs for RA?

Aurelie Najm, MD, PhD

Several abstracts are presenting new compounds, targeting either RA well-known inflammatory pathways or offering new mechanisms of action or therapeutic sequences; these are summarized below.

Read Article
Telemedicine

AI meets Rheumatology: ChatGPT and patient response optimization

Bella Mehta, MBBS, MS

Large language models, such as ChatGPT, are advanced systems trained on vast amounts of text data, far exceeding what a human can read in a lifetime, to understand and generate human-like language. With these tools at our disposal, they are inevitably making their way into healthcare. One notable example is response optimization for SLE patients, as highlighted in abstract #0989.

Read Article
lupus SLE

SLE Preview: abolishing refractory with CAR-T and better B-cell therapies

Md Yuzaiful Md Yusof, MRCP(UK), PhD

Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab.

Read Article
Risk Option Decision

The art of talking about risks with our patients

David Liew, FRACP

On the first day of EULAR 2024, I am debating Janet Pope.

Read Article
RheumNow Podcast square

Is Cannabis Safe? (6.7.2024)

Jack Cush, MD

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!

Read Article
Digital biomarkers are also going to be useful int he future - from devices such as phone / watches.

Bella Mehta bella_mehta ( View Tweet)

Final prep in my hotel room for tomorrow’s big #EULAR2024 opening debate: this David up against the metaphorical (if not physical) Goliath, @Janetbirdope. Data does not adequately justify this JAKi regulatory safety warning, tomorrow I’ll tell you why. Details below ⬇️ @RheumNow https://t.co/rwFtYRlpLY

Links:

David Liew drdavidliew ( View Tweet)
✨ Powerful stories shared at the #EULAR2024 Opening Ceremony including from #PARE Chair @fibrofella https://t.co/Jzfk9LrhV4

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Asking the quintessential Australian question at #EULAR24 by @drdavidliew - does the ORAL surveillance study for JAKi *truly* pass the pub test? @eular_org @Janetbirdope @RheumNow What does #MedTwitter think? https://t.co/bqwPU8XX5S

Links:

Benjamin Sutu benjaminsutu ( View Tweet)
Join us later for a some very exciting pieces of translational science across a AIRDs. All these abstracts sharing one thing in common: tissue, tissue, tissue! 16:30-18:00 Room A8.2 @RheumNow #EULAR2024 https://t.co/HrHP5tmHDD

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Dr. D Aletaha defines The #EULARManifesto, "It is about patient centeredness-- improving quality of care, advocating for patients, timely access to specialists, pushing R&D innovation, integrating technology to make sure every patient gets the care they need." @rheumnow #EULAR24

TheDaoIndex KDAO2011 ( View Tweet)

LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL 3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

#EULAR2024 Opening Ceremony. @DanielAletaha highlighted values of @eular strategies that have been achieved: Patient centredness ✔️ Innovation ✔️ - RheumaFacts, ENTRI, Exams Inclusivity ✔️ To strive on 3 other values by next year under President-Elect @XBaraliakos @RheumNow https://t.co/wDR2vtv3I2

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
📄 #EULARAdvocacy Chair @carmona_loreto discusses the @eular_org manifesto at the #EULAR2024 opening ceremony 🔗You can read the full manifesto and find out more here: https://t.co/6CZuSYpiLl @RheumNow https://t.co/DYcU9I6rmR

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
« We must work together to achieve a future where RMDs are no longer an invisible problem » Wise words from @carmona_loreto during Opening Plenary session #EULAR2024 @RheumNow

Aurelie Najm AurelieRheumo ( View Tweet)

2023 EULAR classification criteria for hand osteoarthritis A EULAR consensus group has established classification criteria for overall hand osteoarthritis (OA) and its subtypes (interphalangeal OA and thumb base OA). https://t.co/wIgjYB2rXF https://t.co/TjSILyC4IT https://t.co/3x6YtXW81u

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Calls on CMS for Enhanced Transparency & Reporting The ACR has submitted its response to the CMS)request for information (RFI) and feedback from stakeholders on how best to enhance MA data capabilities and increase public transparency. https://t.co/vWPXlhmUGo https://t.co/Z8s3PZijqE

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM CASE- 46 yoM with Arthritis (wrists, ankles) and maculopapular Rash (chest, back, legs); prior travel to Caribbean, C. America, HTN, Tachycardia, ESR 104 , nl CRP, but ^d-dimer 990. Scattered alopecia & nasal crusting. Vote your Dx https://t.co/3bdmbnSdlB https://t.co/0R4WK1SKI2

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of 31 FDA Rheum drug approvals betw 1995-2021 showed patient-reported outcomes seldom reported or published. Despite meeting MCID (57%) & significance (85%), 1/3 PROs not reported & 10% remained unpublished (4yrs later) https://t.co/pvGhTxlP03 https://t.co/t3VEHw7FJv

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×